Aardvark Therapeutics AARD
NASDAQ AARD
$4.41 +0.51 (+13.08%)
At close: Oct 21, 2026 · 4:00 PM EDT

Aardvark Therapeutics (AARD) Operating Leases (2024 - 2026)

Updated

Aardvark Therapeutics (AARD) recorded Operating Leases of $276,000 in Q2 2026, up 21.1% from $228,000 a year earlier.

Analysis

Aardvark Therapeutics (AARD) Operating Leases (2024 - 2026) Analysis & Trends

At the end of FY2024, Aardvark Therapeutics reported Operating Leases of $441,000.

  • The Q2 2026 figure is the highest quarterly Operating Leases since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Aardvark Therapeutics 96.45 Mn 22.55 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 276,000.00
Sep 30, 2025 116,000.00
Jun 30, 2025 228,000.00
Mar 31, 2025 336,000.00
Dec 31, 2024 441,000.00
API Access

Aardvark Therapeutics Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=AARD&period=max&api_key=YOUR_API_KEY